Request Demo

Last update 22 Jul 2025

Temozolomide

Last update 22 Jul 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide

+ [27]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors), DNA alkylating agents

Therapeutic Areas

NeoplasmsNervous System DiseasesSkin and Musculoskeletal Diseases+ [10]

Active Indication

Ewing SarcomaMalignant glioma of brainMalignant melanoma, metastatic+ [85]

Inactive Indication

Acoustic NeuromaAcute myeloid leukaemia with 11q23 abnormalityAdrenal Gland Pheochromocytoma+ [96]

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Bristol Myers Squibb Co.

Novartis Pharmaceuticals Corp.

Alliance Foundation Trials LLC

+ [29]

Inactive Organization

Radiation Therapy Oncology Group

NYU Langone Health

Novartis AG

+ [39]

License Organization

Double Bond Pharmaceutical International AB

Institut Gustave Roussy EURL

Belarusian State University

+ [1]

Drug Highest PhaseApproved

First Approval Date

European Union (26 Jan 1999),

AstrocytomaGlioblastoma MultiformeGlioma

RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China)

Structure/Sequence

Molecular FormulaC6H6N6O2

InChIKeyBPEGJWRSRHCHSN-UHFFFAOYSA-N

CAS Registry85622-93-1

1,055

Clinical Trials associated with Temozolomide

NCT01777919

/ Not yet recruitingPhase 2IIT

A PHASE II CLINICAL TRIAL FOR THE EVALUATION OF THE EFFICACY OF DISULFIRAM/COPPER COMBINATION AS AN ADJUVANT AND CONCURRENT CHEMOTHERAPY IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORM

Glioblastoma multiform (GBM) is the most common malignant primary brain tumor in adults. Despite maximal treatment tumor relapse occurs regularly accompanied by unfavourable prognosis. Among other reasons, it is believed that this could be in part due to the existence of the so-called tumor stem cells (TSCs), a cellular subfraction within GBM which escape therapy by being highly resistant to irradiation and chemotherapy and thus constituting the source of tumor recurrence.
GBM, like many other cancers, show a sub-population of aldehyde dehydrogenase (ALDH) overexpressing TSCs. More specifically, ALDH1A1, a cytoplasmatic isoform of ALDH, proved to be a novel stem cell marker in human GBM. In addition, ALDH1A1 has been shown to be a mediator for resistance of GBM to temozolomide (TMZ) and a reliable predictor of clinical outcome; prognosis of patients with a high level of ALDH1A1 expression was poor compared with that of patients with low levels. Consequently, ALDH1A1 may serve as a potential target to improve treatment of human GBM through inhibition of the enzyme.
Disulfiram (DSF) has been used for more than sixty years in the treatment of chronic alcoholism because of the unpleasant symptoms it provokes after ethanol intake. The underlying mechanism is believed to be the accumulation of acetaldehyde in the blood, due to inhibition of the liver ALDHs. Actually, DSF is a strong inhibitor of ALDH1A1 and relatively non-toxic at therapeutic (for chronic alcoholism) doses that can penetrate the blood-brain barrier. In addition, DSF has been shown to be cytotoxic on GBM stem-like cells, inhibiting the growth of TMZ resistant GBM cells and blocking self-renewal by
100% , while it has been identified as an inhibitor of human GBM stem cells in high-throughput chemical screens. Interestingly, a number of these actions were copper-dependent.
In the current Phase II clinical trial, DSF/copper combination will be tested as an adjunctive and concurrent chemotherapy in the treatment of newly diagnosed GBM. According to our hypothesis, initiation of DSF chemotherapy after the resection of the tumor and before the introduction of the standard radio-chemotherapy will inhibit ALDH1A1 of GBM TSCs making them more susceptible to radio-chemotherapy and possibly reducing the recurrence rate of GBM. On the other hand, the addition of copper will probably enhance the cytotoxic effects of DSF possibly through augmentation of its pro-apoptotic and proteasomal inhibitory actions.

Start Date01 Jan 2027

Sponsor / Collaborator

Universität Ulm

[+2]

NCT06816927

/ Not yet recruitingPhase 2IIT

A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)

GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocitrate dehydrogenase (IDH) wildtype newly diagnosed glioblastoma (ndGBM).

Start Date01 Nov 2025

Sponsor / Collaborator

Duke University

NCT07025226

/ Not yet recruitingEarly Phase 1IIT

Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies

This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin and temozolomide work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Quercetin and fisetin are compounds found in plants. They have antioxidant and anti-inflammatory properties and help remove senescent cells, older or damaged cells that have stopped dividing but don't die off as they should and build up in tissues over time. Senescent cells may cause inflammation or damage to nearby healthy cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. Giving medication combinations of dasatinib, quercetin, fisetin and temozolomide may be safe, tolerable and/or effective in treating patients with previously treated glioma with residual disease.

Start Date01 Nov 2025

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Temozolomide

100 Translational Medicine associated with Temozolomide

100 Patents (Medical) associated with Temozolomide

14,625

Literatures (Medical) associated with Temozolomide

31 Dec 2025·Human Vaccines & Immunotherapeutics

Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis

Article

Author: Wang, Hongxin ; Yan, Wei ; Long, Zhi ; Yi, Zhenjie

Glioblastoma is a life-threatening primary malignant brain tumor with an unfavorable prognosis. Contributing factors to its poor outcome include tumor heterogeneity, low mutational burden, and immunosuppression within the tumor microenvironment. Recognizing these challenges, immunotherapeutic strategies have emerged as a promising avenue for glioblastoma treatment. Although several dynamic research and scientific trend have increasingly taken pace in the immunotherapeutic approaches to glioblastoma, systematic bibliometric studies on such trends are few. On this note, this study explores a bibliometric analysis of the research hotspots and trends in glioblastoma immunotherapy. We conducted a search in the Web of Science Core Collection database for articles on glioblastoma immunotherapy published between 2004 and 2024. Using VOSviewer and CiteSpace software, we analyzed collected articles to explore aspects such as country of origin, journal of publication, affiliated institute, authorship, keywords, and citation patterns. As of May 1, 2024, we retrieved 3,729 papers on Glioblastoma Immunotherapy. In the field of glioblastoma immunotherapy, the United States stands out as the leading contributor, with 1,708 publications and a substantial 90,590 citations. Following closely, China has made significant contributions through 926 publications, earning 17,533 citations, while Germany adds to the body of knowledge with 349 publications and 16,355 citations. Furthermore, Authoritative journals in this field include Clinical Cancer Research and Neuro-Oncology. The top five keywords during this period were temozolomide, radiotherapy, dendritic cell, cytotoxic T lymphocyte, and vaccination. Moreover, Hotspots in the field include immune checkpoint inhibitors and chimeric antigen receptor T cell therapy.

31 Dec 2025·NMC case report journal

Favorable Response to Conventional Chemoradiotherapy in Radiation-induced Glioma Harboring Coamplification of PDGFRA, KIT, and KDR: A Case Report and Literature Review

Article

Author: MIZUNO, Reina ; KANEKO-MISHIMA, Masayo ; TANIKAWA, Daisuke ; SAKAKIBARA, Ayaka ; HOMMA, Taku ; SUZUKI, Tomonari ; MISHIMA, Kazuhiko ; OZAWA, Tatsuya ; SAKURADA, Kokyo ; KATO, Shingo ; FUKUOKA, Masayoshi ; EHARA, Takuro ; SHIRAHATA, Mitsuaki

One of the most serious complications of cranial radiotherapy is the development of radiation-induced glioma, which is estimated to occur in 1%-4% of patients who have received cranial irradiation and has a worse prognosis than sporadic glioblastoma. Although comprehensive genetic analysis has recently uncovered the molecular characteristics of radiation-induced glioma, the full picture remains unclear due to its rarity. A 45-year-old man presented with generalized seizures caused by multiple brain tumors involving the right frontal lobe, thalamus, and brainstem. The patient had a history of whole-brain radiotherapy for recurrent Burkitt's lymphoma at the age of 12. He underwent craniotomy, and the histological diagnosis revealed a high-grade glioma with isocitrate dehydrogenase-wildtype, which was presumed to be a radiation-induced glioma that developed 33 years after whole-brain irradiation. Next-generation sequencing identified a CDKN2A/B deletion, as well as coamplification of several receptor tyrosine kinases-encoding genes, including PDGFRA, KIT, and KDR, all of which are located at 4q12. Amplification of this region is broadly observed across cancers and is associated with poor prognosis in sporadic glioblastoma. Nevertheless, the patient received chemoradiotherapy with temozolomide, followed by temozolomide maintenance therapy, resulting in a complete response of all lesions. Although radiation-induced gliomas are generally difficult to treat, our patient unexpectedly responded well to conventional chemoradiotherapy despite the coamplification of multiple receptor tyrosine kinases-encoding genes, which is typically suggestive of an aggressive phenotype. Our case indicates that some radiation-induced gliomas may have distinct molecular characteristics influencing the therapeutic response, which differ from those of sporadic glioblastomas.

31 Dec 2025·ANNALS OF MEDICINE

Comparative efficacy of glioma treatment strategies: an umbrella review of meta-analyses

Review

Author: Yang, Erming ; Gao, Yixuan ; Li, Jun ; Zong, Xiaowen ; Liu, Xuanyu ; Yang, Yao ; Liu, Xinru

OBJECTIVE:

To assess the quality of evidence, identify potential biases, and verify the validity of existing studies on glioma treatment outcomes.

METHODS:

We extracted and analyzed data from systematic reviews and meta-analyses assessing therapies in glioma patients. Our search included PubMed, Embase, Web of Science, and the Cochrane Database up to July 2024. Two authors independently evaluated each meta-analysis for methodological quality using the AMSTAR tool, following established evidence classification guidelines.

RESULTS:

This study evaluated 68 meta-analyses and 389 outcomes from 4,243 articles, classifying 193 outcomes as 'very low' quality, 96 as 'low' quality, 28 (7.2%) as 'high' quality, and 72 (18.5%) as 'moderate' quality, 156 as NS, 231 (59.4%) as Class IV, and 2 (0.005%) as Class III, respectively. High-quality evidence demonstrated that combining Traditional Chinese and Western medicine, adding bevacizumab (BVZ) to chemoradiotherapy (CRT), and other specific treatments improved overall survival (OS). Molecularly targeted drugs combined with temozolomide (TMZ) and radiotherapy (RT), as well as standard therapy augmented with anti-vascular endothelial growth factor or BVZ, prolonged progression-free survival (PFS). Additionally, treatments involving RT with TMZ or TMZ alone increased adverse events, whereas high-quality evidence showed that integrated Traditional Chinese and Western medicine, compared to Western medicine alone, reduced bone marrow suppression and gastrointestinal issues, enhancing treatment efficacy.

CONCLUSIONS:

High-quality evidence indicates that targeted therapy, immunotherapy, CRT, integrated Chinese and Western medicine, gene therapy, and combinations of targeted therapies with CRT or chemotherapy (CT) can extend OS and PFS in gliomas. However, CT, CRT, and targeted therapies, with or without additional CT or CRT, may increase adverse events. Integrated Chinese and Western medicine alone may reduce adverse effects.

320

News (Medical) associated with Temozolomide

21 Jul 2025

·www.globenewswire.com

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable Stable Disease in Notoriously Difficult-to-Treat Cancer - Confirmed Partial Response (PR) in a patient with a desmoplastic small-round-cell tumor (DSRCT) - Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ewing Sarcoma July 17, 2025 -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the end of the Phase 1 portion of its clinical study evaluating elraglusib monotherapy or in combination with irinotecan, irinotecan plus temozolomide, or with cyclophosphamide plus topotecan in pediatric patients with refractory malignancies (Actuate-1902). Following encouraging signals of activity, particularly in treatment-refractory Ewing Sarcoma (EWS), a small round cell sarcoma that forms in soft tissue and bone, the Company will seek to advance the clinical development program towards a Phase 2 study in children, adolescents, and adults with relapsed/refractory EWS. “Refractory and resistant EWS is one of the most aggressive and underserved cancers affecting children and young adults with very low survival rates,” said Dr. Andrew Mazar, Actuate’s Scientific Co-founder and Chief Operating Officer. “To observe complete responses in this setting is highly unexpected, and these exceptional early results position elraglusib as a potential first-in-class therapy option in an indication where no approved targeted therapies currently exist.” The Phase 1/2 Trial (NCT 04239092), also referred to as Actuate-1902, was an open-label, multicenter study evaluating the safety and efficacy of elraglusib in pediatric patients with relapsed/refractory malignancies, including EWS and other pediatric sarcomas. To date, the study has enrolled ten (10) patients with relapsed/refractory EWS (>1 remission) treated with the combination of elraglusib and topotecan/cyclophosphamide. “We are highly encouraged by the responses observed in refractory and resistant EWS, a disease where treatment options are extremely limited beyond frontline chemotherapy,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “With these promising clinical signals in hand, we are advancing our development plans focused on EWS by pursuing a Phase 2 trial and plan to meet with regulators to discuss potential registration path in this indication.” Of the ten (10) EWS patients enrolled, two (2) patients achieved complete responses by CT and/or complete metabolic responses (CR/CMR), while two (2) had confirmed stable disease. A partial response (PR) was also observed in one patient with a desmoplastic small-round-cell tumor (DSRCT), a small round cell sarcoma that forms in soft tissue. While the sample size specific to Ewing Sarcoma in the 1902 study was small, the responses are viewed as positive evidence of anti-tumor activity in this difficult-to-treat indication, and Actuate plans to further investigate elraglusib’s ability to positively change patients’ potential for successful treatment in a Phase 2 trial in pediatric, adolescent, and adult patients with relapsed/refractory Ewing Sarcoma. The Company is collaborating with key opinion leaders and consortiums with interest in EWS to ensure the design of the upcoming study aligns with both patient needs and regulatory expectations. The Company expects to initiate the trial in 2026, subject to available funding. Ewing sarcoma (EWS) is a highly metastatic form of sarcoma with a peak incidence at the age of 15, that ranks as the second most prevalent primary malignant tumor of childhood and adolescence. Approximately 25% of new EWS patients have metastatic disease when first diagnosed, which is the most significant predictor of poor survival. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

07 Jul 2025

·www.prnewswire.com

Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid

Validation Data on 60 Patients published in Cancer Genetics CHICAGO, July 7, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system (CNS) cancers, announced the results of the analytical validation study of the Belay Vantage™ assay for detection of MGMT (Methylation of the O6-methylguanine-DNA methyl-transferase) promoter methylation in cerebrospinal fluid (CSF) for primary and metastatic CNS cancers as reported in Cancer Genetics. The assay uses quantitative polymerase chain reaction (qPCR) on DNA extracted from CSF and has an analytical sensitivity of 95.5% and specificity of 100%. . MGMT promoter methylation testing is recommended in all high-grade gliomas. MGMT is one of the strongest prognostic and predictive biomarkers in glioblastoma, an aggressive cancer with a prognosis of six months or less that accounts for nearly 50% of all primary brain malignancies. Positive MGMT status is associated with a more favorable response to alkylating chemotherapies such as Temozolomide (TMZ). The Belay Vantage™ assay evaluates MGMT promoter methylation status through innovative and minimally invasive sampling of CSF for individuals with known or suspected CNS tumors using low input DNA (5 ng). This represents a distinct advantage over the current method of MGMT testing where invasive biopsy or resection is used to obtain patient samples and 40–250 ng of vital CNS tissue is required. Importantly, the study demonstrates the use of just 2–3 ml of CSF, significantly less than that used by standard of care cytology and flow cytometry, enabling easy implementation into existing clinical workflows. Vantage is the first to use an enzymatic conversion method that maintains integrity of the patient's DNA and minimizes degradation, thereby increasing ability to process DNA downstream, improving accuracy. In contrast, currently available commercial tests use bisulfite conversion that cause DNA damage. The novelty of performing this assay directly from CSF versus tissue facilitates a rapid 3-day turnaround. When ordered with Summit™, Belay's pioneering CSF-based tumor-derived genomic profiling assay for patients with CNS cancer, the turnaround is 7–10-days. "We are grateful to have the opportunity to bring novel and essential testing such as Vantage and Summit to clinicians in order to serve patients with these conditions. I am appreciative of our team members at Belay and Johns Hopkins University who work diligently in providing innovative solutions to inform diagnosis and management of brain cancer," said Brian Coe, Co-founder and Chief Executive Officer of Belay Diagnostics. About Belay Diagnostics Belay Diagnostics is focused on pioneering diagnostic technologies that transform the CNS cancer journey. Belay's Summit™ and Vantage™ advanced liquid biopsy tests in CSF provide molecular characterization that can markedly enhance diagnostic accuracy, tumor classification, predictive prognosis, therapeutic actionability and clinical trial options for those with CNS tumors and malignancies. Our mission is to serve patients and those who care for them. Together, we can help patients with CNS tumors find a path forward. Belay Diagnostics | Brain & Spinal Cord Cancer Testing SOURCE Belay Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

03 Jun 2025

·pipelinereview.com

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

NEW YORK, NY, USA I June 02, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced new long-term clinical data from its fully enrolled Phase 1 trial of INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM). The data were presented in an oral session on May 30 th at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. “Half of the patients who received multiple doses remained progression free for greater than a year and a half, demonstrating functional recoveries, with several patients also having the ability to return to work. No new relapses have been reported since the last clinical update in October 2024” stated Burt Nabors, M.D., Division Director, Neuro-Oncology at the Heersink School of Medicine at the University of Alabama at Birmingham and Principal Investigator of the study. “These early data highlight the potential of repeated intracranial dosing of IN8bio’s gamma-delta T cells to extend mPFS in GBM, including in patients with chemotherapy-resistant tumors.” The Phase 1 results of INB-200 demonstrate that repeated dosing of IN8bio’s proprietary Drug Resistant Immunotherapy (DRI) – which utilizes genetically modified gamma-delta T cells delivered directly into the brain – in combination with SOC maintenance chemotherapy (temozolomide), led to an mPFS of 16.1 months. This represents an improvement of more than double (+9.2 months or +132.6%) the historical mPFS of 6.9 months under the SOC Stupp protocol. These mPFS results have already surpassed the historical mOS of 14.6 months associated with the SOC Stupp protocol alone. By comparison, a 2 to 3 month improvement in mPFS has historically been considered as clinically significant and the bar for approval by the Food and Drug Administration (FDA). Importantly, no dose-limiting toxicities (DLTs), CRS, or ICANS have been observed among patients treated with INB-200 (n=13). The majority of adverse events were Grade 1-2 and consistent with those typically associated with radiation and temozolomide. No treatment-related deaths have occurred. Highlights from the Clinical Data as of May 31, 2025: INB-200 INB-400 “Our goal is to achieve deeper responses and eliminate more cancer cells to ultimately extend the time patients can remain progression free and alive,” stated William Ho, CEO and cofounder of IN8bio. “The data presented at ASCO by Dr. Nabors speaks to the potential of IN8bio’s gamma-delta T cells to provide a game-changing immunotherapy for this dire and life-threatening cancer. We believe that INB-200 represents a novel direction in therapy for the treatment of solid tumor cancers like GBM. The complete data from our Phase 1 trial and supporting data from our Phase 2 trial represent the first time a gamma-delta T cell therapy has shown the potential to extend mPFS beyond historical benchmarks.” IN8bio’s approach delivers gamma-delta T cells directly to the tumor cavity after surgery, applying sustained immune pressure to eliminate residual cancer cells. The Company’s DRI technology is designed to treat newly diagnosed GBM by harnessing the natural tumor-targeting power of gamma-delta T cells and the sensitizing effects of chemotherapy. This approach aims to eliminate the chemo-resistant cancer and stem cells that often survive SOC treatment and can lead to relapse. Conference Call Details IN8bio will host a conference call and webcast featuring Dr. Burt Nabors, the Principal Investigator, today, Monday, June 2, 2025 at 8:30 am EDT to review the updated clinical data from the ASCO presentation. The webcast can be accessed by clicking this link and can also be accessed on the Events & Presentations page of the Company’s website. To participate in the live call, please register using this link . It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will be informed of the dial-in number and will be provided a unique PIN. (1) Historical reported mPFS and mOS from Stupp Protocol (surgery, radiotherapy plus maintenance temozolomide); doi: 10.1056/NEJMoa043330 About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and advancing novel γδ T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com. SOURCE: IN8bio

Cell TherapyPhase 1ImmunotherapyASCOPhase 2

100 Deals associated with Temozolomide

External Link

KEGG	Wiki	ATC	Drug Bank
D06067	Temozolomide	L01AX03	DB00853

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ewing Sarcoma	Japan	Ohara Pharmaceutical Co., Ltd.	21 Feb 2019
Ewing Sarcoma	Japan	MSD KK (Tokyo)	21 Feb 2019
Malignant glioma of brain	European Union	Teva Pharmaceuticals Europe BV	28 Jan 2010
Malignant glioma of brain	Iceland	Teva Pharmaceuticals Europe BV	28 Jan 2010
Malignant glioma of brain	Liechtenstein	Teva Pharmaceuticals Europe BV	28 Jan 2010
Malignant glioma of brain	Norway	Teva Pharmaceuticals Europe BV	28 Jan 2010
Malignant melanoma, metastatic	Australia	Merck Sharp & Dohme (Australia) Pty Ltd.	13 Nov 2009
Glioblastoma	China	Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.	30 Apr 2004
Astrocytoma	European Union	Merck Sharp & Dohme BV	26 Jan 1999
Astrocytoma	Iceland	Merck Sharp & Dohme BV	26 Jan 1999
Astrocytoma	Liechtenstein	Merck Sharp & Dohme BV	26 Jan 1999
Astrocytoma	Norway	Merck Sharp & Dohme BV	26 Jan 1999
Glioblastoma Multiforme	European Union	Merck Sharp & Dohme BV	26 Jan 1999
Glioblastoma Multiforme	Iceland	Merck Sharp & Dohme BV	26 Jan 1999
Glioblastoma Multiforme	Liechtenstein	Merck Sharp & Dohme BV	26 Jan 1999
Glioblastoma Multiforme	Norway	Merck Sharp & Dohme BV	26 Jan 1999
Glioma	European Union	Merck Sharp & Dohme BV	26 Jan 1999
Glioma	Iceland	Merck Sharp & Dohme BV	26 Jan 1999
Glioma	Liechtenstein	Merck Sharp & Dohme BV	26 Jan 1999
Glioma	Norway	Merck Sharp & Dohme BV	26 Jan 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuroblastoma	NDA/BLA	European Union	ORPHELIA Pharma SAS	14 Nov 2024
Uterine Leiomyosarcoma	Phase 3	United States	Alliance for Clinical Trials in Oncology	30 Mar 2022
Brain Stem Glioma	Phase 3	United States	National Cancer Institute	26 Jan 2011
Brain Stem Glioma	Phase 3	Canada	National Cancer Institute	26 Jan 2011
Cerebral Astrocytoma, Adult	Phase 3	United States	National Cancer Institute	26 Jan 2011
Cerebral Astrocytoma, Adult	Phase 3	Canada	National Cancer Institute	26 Jan 2011
High grade glioma	Phase 3	United States	National Cancer Institute	26 Jan 2011
High grade glioma	Phase 3	Canada	National Cancer Institute	26 Jan 2011
Pediatric Cerebellar Astrocytoma	Phase 3	United States	National Cancer Institute	26 Jan 2011
Pediatric Cerebellar Astrocytoma	Phase 3	Canada	National Cancer Institute	26 Jan 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04574856 (Phase 2 Study of Multiparametric Magnetic Resonance Imaging-Guided High-Dose Response-Adaptive Radiation Therapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma, Pubmed \| Int J Radiat Oncol Biol Phys)	Phase 2	Glioblastoma	30	Temozolomide (Patients with newly diagnosed GBM)	ztbgyifyxg(pwyvgkzjdm) = fjlgglgipj xajbdxloyd (jglfjdaqsa ) View more	Positive	01 Jul 2025
NCT00629343 (CTgov)	Phase 1	Mesothelioma, Malignant \| Soft Tissue Sarcoma	27	Temozolomide+Azacitidine	tcweihunct = wvszspfnar yhpizlkkta (jaealfnmbn, worgcabyzj - crsverccaz) View more	-	05 Jun 2025
NCT00626990 (CATNON, ASCO2025)	Phase 3	Glioma Adjuvant IDH mutation \| total copy number alterations \| methylation subtype	751	Radiotherapy alone	mizvadpgux(jbrfuikcrr) = 8.5 years fakgcfsaoh (utnooxpvdz ) View more	Positive	30 May 2025
				Concurrent Temozolomide
NCT02761070 (JCOG1308C, ASCO2025)	Phase 3	Recurrent Glioblastoma	146	Bevacizumab	dfoycjfove(bodbzjqymj) = 19.4% in arm A esuedoxlve (cvwdxiaylq ) View more	Negative	30 May 2025
				Dose-dense Temozolomide
BT008 (ASCO2025)	Phase 1/2	High grade glioma Adjuvant	34	temozolomideTMZde (MB-FUS+TMZ)	ajjkhlntay(qsskwefyqc) = No serious procedure-related AEs were seen, with the most common AEs being mild, self-resolving qgxwuwwrzb (cwpfnijlfr ) View more	Positive	30 May 2025
				temozolomide (External cohort)
NCT04280848 (Phase II study of UCPVax in newly diagnosed glioblastoma, ASCO2025)	Phase 2	Glioblastoma Adjuvant non-mutated IDH1 \| unmethylated MGMT status	-	UCPVax + Temozolomide	jxvsdksxef(luxdejfkxg) = vaqwrfqdrd fwwqlooxsg (kaasuuyjag ) View more	Positive	30 May 2025
ASCO2025	Phase 2	High Risk Neuroblastoma	34	HITS (Irinotecan, Temozolomide, Naxitamab, GM-CSF)	fscfxowhkq(vtxyckwwli) = gjzfuxakxf vujsnrmtyr (evojlbjcls ) View more	Positive	30 May 2025
				NICE (Naxitamab, GM-CSF, Ifosfamide, Carboplatin, Etoposide)	fscfxowhkq(vtxyckwwli) = psxwbxeqwi vujsnrmtyr (evojlbjcls ) View more
ASCO2025	Not Applicable	Leiomyosarcoma Maintenance	20	Doxorubicin plus dacarbazine	usbcjccoec(cbnvdekzjk) = dbacxbblze wpuonkaicc (rpaegduwah )	Positive	30 May 2025
ASCO2025	Not Applicable	-	159	temozolomide (Pancreatic NETs (PNETs))	osxfbassdd(lxbkjcahjq) = lwvonvnjtu xxwmdxdula (lrpqthrzct ) View more	Positive	30 May 2025
				temozolomide (Gastrointestinal NETs (GINETs))	osxfbassdd(lxbkjcahjq) = egcnzeuicl xxwmdxdula (lrpqthrzct ) View more
NCT03554473 (CTgov)	Phase 1/2	Recurrent Lung Small Cell Carcinoma \| Small Cell Carcinoma \| Small intestine carcinoma recurrent	37	Epinephrine+CT scan+Acetaminophen+Temozolomide+Dexamethasone+M7824+Diphenhydramine (Arm A/M7824 (MSB0011359C) Monotherapy)	tmzbpcsqiz = tiivctedtv synuyizuxk (oueccuvkxi, gfyudnzdin - brqyaiyrix) View more	-	09 May 2025
				Epinephrine+CT scan+Acetaminophen+Dexamethasone+M7824+Diphenhydramine+Topotecan (Arm B/M7824 (MSB0011359C) Plus Topotecan)	tmzbpcsqiz = dkgfgzckyf synuyizuxk (oueccuvkxi, qybcrtszxw - ezrwzfatiw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis